Eicosanoids As An Agonists;
Discovery of G Protein-Biased EP2 Receptor Agonists
†Medicinal Chemistry Research Laboratories, ‡Department of Biology & Pharmacology, and §Discovery Research Alliance, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
∥ Department of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8571, Japan
ACS Med. Chem. Lett., 2016, 7 (3), pp 306–311
DOI: 10.1021/acsmedchemlett.5b00455
Publication Date (Web): January 4, 2016
Copyright © 2016 American Chemical Society
Abstract
To identify G protein-biased and highly subtype-selective EP2 receptor agonists, a series of bicyclic prostaglandin analogues were designed and synthesized. Structural hybridization of EP2/4 dual agonist 5 and prostacyclin analogue 6, followed by simplification of the ω chain enabled us to discover novel EP2 agonists with a unique prostacyclin-like scaffold. Further optimization of the ω chain was performed to improve EP2 agonist activity and subtype selectivity. Phenoxy derivative 18a showed potent agonist activity and excellent subtype selectivity. Furthermore, a series of compounds were identified as G protein-biased EP2 receptor agonists. These are the first examples of biased ligands of prostanoid receptors.
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.5b00455.
- Experimental procedures of compounds, characterization data, and conditions of the biological assays (PDF)
These Side Chaines (arufa + omega)could be attached to Quinolone/Quunoline Scaffolds for Further Developement.
返信削除